Novartis in Lead to Acquire Cancer-Drug Maker MorphoSys, Reuters Reports
--Novartis is in advanced talks with MorphoSys to acquire the cancer-drug developer with a market value of 1.6 billion euros ($1.73 billion), Reuters reports, citing unnamed sources.
--The Swiss drug maker is ahead of rival Incyte Corp, which has also made an offer for MorphoSys, Reuters reports.
--At 1547 GMT, Frankfurt shares in MorphoSys were up 33% to EUR56.20.
--Novartis and MorphoSys didn't immediately responded to requests for comment.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
February 05, 2024 11:29 ET (16:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks